Clene Inc. (CLNN) Stock

Clene Inc. (CLNN) is a Healthcare stock trading at $6.00 (as of 2026-06-18), with a market capitalization of $83.83M and a trailing P/E of -2.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Clene Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing clean-surfaced nanotechnology (CSN) therapeutics. Its product pipeline includes CNM-Au8 for neurological indications such as ALS and chronic optic neuropathy, and other CSN candidates including CNM-AgZn17 and CNM-ZnAg for infectious disease and wound-related uses.

Valuation — source: SEC EDGAR (first-party)
Price	$6.00
Market Cap	$83.83M
P/E Ratio	-2.2
EV / EBITDA	-4.4
Price / Book	-3.97
Price / Sales	556.91
DCF Value (model)	$-27.93
DCF Upside vs Price	-565.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$200000.00
Net Margin	-13086.5%
Return on Equity	178.2%
Debt / Equity	-0.94
Current Ratio	1.94
Revenue Growth (YoY)	-41.5%
EPS Growth (YoY)	-53.3%
FCF Growth (YoY)	-12.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	-26.93 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-110.7%
vs Industry	-113.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Boxer Capital Management, LLC ($2.35M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Robert Etherington
Employees	75
Country	US
IPO Date	2018-10-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.